Beam Therapeutics Inc. Increase (Decrease) in Accounts Payable
Beam Therapeutics Inc. (BEAM) reported Increase (Decrease) in Accounts Payable of $3.43 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccountsPayable · last filed 2026-08-04
- Beam Therapeutics Inc. increase (decrease) in accounts payable for the quarter ending 2026-06-30 was $1.21M, a 54.05% decline year-over-year.
- Beam Therapeutics Inc. increase (decrease) in accounts payable for the quarter ending 2026-03-31 was $2.22M, a 41.58% decline year-over-year.
- Beam Therapeutics Inc. increase (decrease) in accounts payable for the quarter ending 2025-12-31 was $1.19M.
- Beam Therapeutics Inc. increase (decrease) in accounts payable for the quarter ending 2025-09-30 was -$1.59M.
- Beam Therapeutics Inc. increase (decrease) in accounts payable for fiscal 2025 was $6.04M, a 234.26% increase from fiscal 2024.
- Beam Therapeutics Inc. increase (decrease) in accounts payable for fiscal 2024 was $1.81M.
- Beam Therapeutics Inc. increase (decrease) in accounts payable for fiscal 2023 was -$7.58M, a 419.34% decline from fiscal 2022.
- Beam Therapeutics Inc. increase (decrease) in accounts payable for fiscal 2022 was $2.37M, a 190.10% increase from fiscal 2021.
| Period end | Increase (Decrease) in Accounts Payable 3 month | Increase (Decrease) in Accounts Payable 6 month | Increase (Decrease) in Accounts Payable 9 month | Increase (Decrease) in Accounts Payable 12 month |
|---|---|---|---|---|
| 2026-06-30 | $1.21M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-04 | $3.43M 10-Q · filed 2026-08-04 | $4.62M derived: sum of 3 quarters · filed 2026-08-04 | $3.04M derived: sum of 4 quarters · filed 2026-08-04 |
| 2026-03-31 | $2.22M 10-Q · filed 2026-05-07 | $3.41M derived: sum of 2 quarters · filed 2026-05-07 | $1.82M derived: sum of 3 quarters · filed 2026-05-07 | $4.46M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-12-31 | $1.19M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | -$395.00K derived: sum of 2 quarters · filed 2026-02-24 | $2.25M derived: sum of 3 quarters · filed 2026-08-04 | $6.04M 10-K · filed 2026-02-24 |
| 2025-09-30 | -$1.59M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | $1.05M derived: sum of 2 quarters · filed 2026-08-04 | $4.85M 10-Q · filed 2025-11-04 | $4.30M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-06-30 | $2.64M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-04 | $6.43M 10-Q · filed 2026-08-04 | $5.88M derived: sum of 3 quarters · filed 2026-08-04 | $5.18M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-03-31 | $3.79M 10-Q · filed 2026-05-07 | $3.24M derived: sum of 2 quarters · filed 2026-05-07 | $2.54M derived: sum of 3 quarters · filed 2026-05-07 | $4.32M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | -$550.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | -$1.25M derived: sum of 2 quarters · filed 2026-02-24 | $522.00K derived: sum of 3 quarters · filed 2026-02-24 | $1.81M 10-K · filed 2026-02-24 |
| 2024-09-30 | -$700.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | $1.07M derived: sum of 2 quarters · filed 2025-11-04 | $2.36M 10-Q · filed 2025-11-04 | $589.00K derived: sum of 4 quarters · filed 2026-02-24 |
| 2024-06-30 | $1.77M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-05 | $3.06M 10-Q · filed 2025-08-05 | $1.29M derived: sum of 3 quarters · filed 2026-02-24 | -$1.76M derived: sum of 4 quarters · filed 2026-02-24 |
| 2024-03-31 | $1.28M 10-Q · filed 2025-05-06 | -$483.00K derived: sum of 2 quarters · filed 2026-02-24 | -$3.53M derived: sum of 3 quarters · filed 2026-02-24 | -$6.06M derived: sum of 4 quarters · filed 2026-02-24 |
| 2023-12-31 | -$1.77M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | -$4.81M derived: sum of 2 quarters · filed 2026-02-24 | -$7.35M derived: sum of 3 quarters · filed 2026-02-24 | -$7.58M 10-K · filed 2026-02-24 |
| 2023-09-30 | -$3.04M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-05 | -$5.58M derived: sum of 2 quarters · filed 2024-11-05 | -$5.81M 10-Q · filed 2024-11-05 | -$2.91M derived: sum of 4 quarters · filed 2025-02-25 |
| 2023-06-30 | -$2.53M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-06 | -$2.77M 10-Q · filed 2024-08-06 | $135.00K derived: sum of 3 quarters · filed 2025-02-25 | $758.00K derived: sum of 4 quarters · filed 2025-02-25 |
| 2023-03-31 | -$231.00K 10-Q · filed 2024-05-07 | $2.67M derived: sum of 2 quarters · filed 2025-02-25 | $3.29M derived: sum of 3 quarters · filed 2025-02-25 | $3.39M derived: sum of 4 quarters · filed 2025-02-25 |
| 2022-12-31 | $2.90M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-25 | $3.52M derived: sum of 2 quarters · filed 2025-02-25 | $3.63M derived: sum of 3 quarters · filed 2025-02-25 | $2.37M 10-K · filed 2025-02-25 |
| 2022-09-30 | $623.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-08 | $725.00K derived: sum of 2 quarters · filed 2023-11-08 | -$527.00K 10-Q · filed 2023-11-08 | $1.63M derived: sum of 4 quarters · filed 2024-02-27 |
| 2022-06-30 | $102.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | -$1.15M 10-Q · filed 2023-08-08 | $1.01M derived: sum of 3 quarters · filed 2024-02-27 | -$714.00K derived: sum of 4 quarters · filed 2024-02-27 |
| 2022-03-31 | -$1.25M 10-Q · filed 2023-05-10 | $907.00K derived: sum of 2 quarters · filed 2024-02-27 | -$816.00K derived: sum of 3 quarters · filed 2024-02-27 | $232.00K derived: sum of 4 quarters · filed 2024-02-27 |
| 2021-12-31 | $2.16M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-27 | $436.00K derived: sum of 2 quarters · filed 2024-02-27 | $1.48M derived: sum of 3 quarters · filed 2024-02-27 | $818.00K 10-K · filed 2024-02-27 |
| 2021-09-30 | -$1.72M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-07 | -$675.00K derived: sum of 2 quarters · filed 2022-11-07 | -$1.34M 10-Q · filed 2022-11-07 | -$1.15M derived: sum of 4 quarters · filed 2023-02-28 |
| 2021-06-30 | $1.05M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-09 | $382.00K 10-Q · filed 2022-08-09 | $576.00K derived: sum of 3 quarters · filed 2023-02-28 | $495.00K derived: sum of 4 quarters · filed 2023-02-28 |
| 2021-03-31 | -$666.00K 10-Q · filed 2022-05-09 | -$472.00K derived: sum of 2 quarters · filed 2023-02-28 | -$553.00K derived: sum of 3 quarters · filed 2023-02-28 | -$135.00K derived: sum of 4 quarters · filed 2023-02-28 |
| 2020-12-31 | $194.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28 | $113.00K derived: sum of 2 quarters · filed 2023-02-28 | $531.00K derived: sum of 3 quarters · filed 2023-02-28 | $60.00K 10-K · filed 2023-02-28 |
| 2020-09-30 | -$81.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-08 | $337.00K derived: sum of 2 quarters · filed 2021-11-08 | -$134.00K 10-Q · filed 2021-11-08 | $2.64M derived: sum of 4 quarters · filed 2022-02-28 |
| 2020-06-30 | $418.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-10 | -$53.00K 10-Q · filed 2021-08-10 | $2.72M derived: sum of 3 quarters · filed 2022-02-28 | $2.50M derived: sum of 4 quarters · filed 2022-02-28 |
| 2020-03-31 | -$471.00K 10-Q · filed 2021-05-11 | $2.30M derived: sum of 2 quarters · filed 2022-02-28 | $2.08M derived: sum of 3 quarters · filed 2022-02-28 | $5.14M derived: sum of 4 quarters · filed 2022-02-28 |
| 2019-12-31 | $2.77M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-28 | $2.55M derived: sum of 2 quarters · filed 2022-02-28 | $5.61M derived: sum of 3 quarters · filed 2022-02-28 | $4.09M 10-K · filed 2022-02-28 |
| 2019-09-30 | -$219.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-10 | $2.84M derived: sum of 2 quarters · filed 2020-11-10 | $1.32M 10-Q · filed 2020-11-10 | |
| 2019-06-30 | $3.06M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-12 | $1.54M 10-Q · filed 2020-08-12 | ||
| 2019-03-31 | -$1.52M 10-Q · filed 2020-05-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Denali Therapeutics Inc. (DNLI) | United States | $3.274B | -8.04 |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Tarsus Pharmaceuticals, Inc. (TARS) | United States | $3.329B | -58.60 |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |